Tratamento da neuromielite óptica: uma revisão baseada em evidências by Sato, Douglas et al.
  Universidade de São Paulo
 
2012
 
Treatment of neuromyelitis optica: an evidence
based review
 
 
Arq. Neuro-Psiquiatr.,v.70,n.1,p.59-66,2012
http://www.producao.usp.br/handle/BDPI/38085
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade Scielo
59
VIEWS AND REVIEWSDOI: Xxxxxxxxxxxxxxxxxxxxx
Treatment of neuromyelitis optica:  
an evidence based review
Tratamento da neuromielite óptica: uma revisão baseada em evidências
Douglas Sato1,2, Dagoberto Callegaro2, Marco Aurélio Lana-Peixoto3, Kazuo Fujihara4, on behalf of Brazilian 
Committee for Treatment and Research in Multiple Sclerosis (BCTRIMS)
Neuromyelitis optica (NMO) is an inflammatory dis-
ease of the central nervous system (CNS) characterized by 
severe optic neuritis (ON) and transverse myelitis (TM)1. 
Aquaporin-4 (AQP-4) antibody, also known as NMO-IgG, an 
autoantibody exclusively detected in the sera of NMO, is di-
rected against AQP-4, a water channel richly expressed on 
foot processes of astrocytes in the CNS2,3. In most series of 
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ABSTRACT
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by severe optic neuritis and transverse 
myelitis, usually with a relapsing course. Aquaporin-4 antibody is positive in a high percentage of NMO patients and it is directed against 
this water channel richly expressed on foot processes of astrocytes. Due to the severity of NMO attacks and the high risk for disability, treat-
ment should be instituted as soon as the diagnosis is confirmed. There is increasing evidence that NMO patients respond differently from 
patients with multiple sclerosis (MS), and, therefore, treatments for MS may not be suitable for NMO. Acute NMO attacks usually are treated 
with high dose intravenous corticosteroid pulse and plasmapheresis. Maintenance therapy is also required to avoid further attacks and it 
is based on low-dose oral corticosteroids and non-specific immunosuppressant drugs, like azathioprine and mycophenolate mofetil. New 
therapy strategies using monoclonal antibodies like rituximab have been tested in NMO, with positive results in open label studies. However, 
there is no controlled randomized trial to confirm the safety and efficacy for the drugs currently used in NMO.
Key words: neuromyelitis optica, therapy, aquaporin 4, plasmapheresis, steroids, azathioprine, mycophenolic acid, monoclonal antibodies, 
mitoxantrone, cyclophosphamide, interferon-beta.
RESUMO
Neuromielite óptica (NMO) é uma doença inflamatória do sistema nervoso central caracterizada por grave neurite óptica e mielite transver-
sa, com um curso usualmente recorrente. O anticorpo contra aquaporina-4 é positivo em grande porcentagem dos pacientes com NMO e se 
liga a este canal de água altamente expresso nos processos pediosos dos astrócitos. Devido à gravidade dos ataques de NMO e ao elevado 
risco de incapacidade, o tratamento deve ser instituído tão logo o diagnostico seja confirmado. Existem evidências crescentes de que pa-
cientes com NMO respondem de forma diferente dos pacientes com esclerose múltipla (EM) e, portanto, os tratamentos utilizados na EM 
podem não ser adequados para NMO. Os quadros agudos de NMO são tratados com pulsos de corticosteroides em altas doses e plasmafé-
rese. O tratamento de manutenção também deve ser instituído para evitar ataques subsequentes e é baseado em corticosteroides orais em 
baixas doses ou imunossupressores, como a azatioprina e o micofenolato mofetil. Novas estratégias de tratamento utilizando anticorpos 
monoclonais como rituximab têm sido avaliadas para NMO, com resultados positivos em estudos abertos. Entretanto, não existem estudos 
clínicos controlados, randomizados, para confirmar a segurança e eficácia dos tratamentos atualmente utilizados na NMO.
Palavras-Chave: neuromielite óptica, terapia, aquaporina 4, plasmaferese, esteróides, azatioprina, ácido micofenólico, anticorpos 
monoclonais, mitoxantrona, ciclofosfamida, interferon-beta.
NMO, more than half of cases are positive for AQP-4 antibody. 
In 2006, Wingerchuk et al.4 proposed the revised diagnostic 
criteria of NMO that incorporated AQP-4 antibody status. For 
definite NMO, the criteria require (A) ON, (B) TM and (C) at 
least two of three supportive criteria: (1) contiguous spinal 
cord lesion in the magnetic resonance imaging (MRI) extend-
ing over three vertebral segments; (2) brain MRI not meeting 
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diagnostic criteria for multiple sclerosis (MS); (3) serum posi-
tivity for AQP-4 antibody. 
NMO treatment has two main objectives: one is to con-
trol the inflammatory damage in acute attacks and the other 
one is a maintenance treatment to avoid relapses. The former 
is based on high dose intravenous corticosteroids and plas-
mapheresis5; the latter is based on low-dose corticosteroids 
and immunossupressants6,7. Additionally, there is evidence 
that AQP-4 antibody titers are reduced in patients without 
relapses under immunosuppressant treatment8,9. Although 
NMO attacks are related to severe disability, there are some 
evidences that NMO patients remain neurologically stable 
between them, without evidence of progressive deterioration 
like in MS1. Therefore, it is crucial that treatment is started as 
early as possible to avoid new relapses and further disability.
For this review, the English-language literature was system-
atically searched using Pubmed (National Library of Medicine) 
with the keywords neuromyelitis optica, and treatment was 
accessed on 20th July 2011, resulting in 394 articles. All articles 
available had the abstract analyzed and full article review was 
performed once considered relevant. Additional articles refer-
enced in bibliographies from these articles were also reviewed. 
Case reports that revealed further insights into NMO, not iden-
tified in case series analyzed, were included in this review.
LEVELS Of EVIDENCE
In this review, we used levels of evidence from the Agency 
for Health Care Policy and Research (also known as Agency for 
Healthcare Research and Policy)10 (Table 1) and the recommen-
dation grades published for use in clinical guidelines from the 
American College of Chest Physicians Task Force (Table 2)11. We 
have classified the available studies in NMO accordingly and 
provided the recommendations for each treatment (Table 3).
CORTICOSTEROIDS
Corticosteroids have been the mainstay treatment for NMO 
in both acute and maintenance phase. Methylprednisolone 
has been used since 1970 as a potent anti-inflammatory or im-
munosuppressant agent in the treatment of a variety of diseas-
es including those of hematologic, allergic, inflammatory, neo-
plastic and autoimmune origin. In addition, it is also widely 
used in prevention and treatment of graft-versus-host disease 
following allogeneic bone marrow transplantation and acute 
spinal cord injury. Corticosteroids exert a wide array of physi-
ologic effects including modulation of carbohydrate, protein 
and lipid metabolism, and maintenance of fluid and electrolyte 
homeostasis. Moreover, cardiovascular, immunologic, muscu-
loskeletal, endocrine and neurologic physiologic functions are 
influenced by corticosteroids. Therefore, not only the positive 
effects can be observed, but also many adverse events can be 
originated from corticosteroids use. These adverse events can 
be seen acutely like mood/psychic changes, fluid retention 
with circulatory overload, hyperglycemia, hypokalemia and in-
creased ocular pressure. Chronic corticosteroid use may pro-
mote other side effects like hypertension, hirsutism, Cushing’s 
syndrome, hyperlipidemia, diabetes mellitus, gastrointestinal 
hemorrhage, aseptic necrosis and bone fractures. 
The mechanism of action of corticosteroids is not com-
pletely understood, but many of their genomic functions orig-
inate from regulation of gene expression subsequent to bind-
ing specific intracellular receptors and translocation into the 
nucleus12. More recently, there have been observed evidences 
that corticosteroids in high doses, as used in high dose intra-
venous methylprednisolone (HIMP), have significant non-ge-
nomic effects, which may explain the rapid clinical response 
after infusion. These effects are probably mediated by a direct 
effect on cellular membranes and mitochondrial function, in-
ducing a reduction of adenosine-5’-triphosphate production 
and promoting cellular apoptosis. Furthermore, HIMP also 
reduces the mitogen-induced increase of cytoplasmic calci-
um concentration and inhibits cation cycling across the plas-
ma membrane with only a minimal effect on intracellular 
protein synthesis. The genomic and non-genomic effects may 
explain the positive effects of corticosteroids in NMO, induc-
ing a reduction of inflammation, apoptosis of leukocytes, sup-
pression of migration of polymorphonuclear leukocytes and 
reversal of increased capillary permeability.
Although the clinical efficacy of corticosteroids have 
been established in meta-analysis evaluating the treatment 
of neuroimmunological diseases13, only few clinical studies 
have rigorously investigated the efficacy and safety of cor-
ticosteroids in NMO. Consequently, the current practice of 
corticosteroids use in NMO is mainly based on few open-la-
bel studies and personal experience on treating other CNS 
autoimmune diseases.
The first open-label study in NMO evaluated the treatment 
of seven newly diagnosed NMO patients with long-term pred-
nisone and azathioprine, with a follow-up every two months 
for at least 18 months6. Patients had no relapses during the ob-
servation period, and Expanded Disability Status Scale (EDSS) 
reduced from a mean of 8.2 at baseline to 4 at 18 months. A 
subsequent study reviewed related 25 patients with NMO who 
met the 1999 Wingerchuk’s criteria and identified nine patients 
with long-term use of corticosteroid monotherapy7. The annu-
al relapse rate was significantly lower under use of corticoster-
oids than the period without the drug (median 0.49 vs. 1.48). 
Still more interesting, the authors also observed that the odds 
ratio for the period with 10 mg/day or less was 8.71 if com-
pared with 10 mg/day or over, suggesting that dose tapering 
below 10 mg/day for relapse prevention should be prescribed 
carefully, as it may be less than the required for the majority of 
patients for relapse prevention.
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Another evidence that corticosteroids are useful to pre-
serve normal nerve function in NMO is a retrospective study 
on NMO patients with optic neuritis relapse, which correlat-
ed the number of relapses, early corticosteroids intervention 
and a loss in retinal nerve fiber layer thickness (RNFLT)14. The 
overall RNFL was thinner in patients in the NMO group than 
in the MS (63.84 vs. 84.28 μm). The frequency of the ON re-
lapses and the time for beginning the treatment with HIMP 
significantly affected the preservation of the RNFLT.
PLASMAPhERESIS
Plasmapheresis (PE) has been used as an alternative ther-
apy for autoimmune diseases when HIMP is not effective. PE 
Table 1. Classification of evidence levels10.
Ia Evidence obtained from meta-analysis of randomized 
controlled trials
Ib Evidence obtained from at least one randomized controlled 
trial
IIa Evidence obtained from at least one well-controlled study 
without randomization
IIb Evidence obtained from at least one other type of well-
designed quasi-experimental study
III Evidence obtained from well-designed, non-experimental 
descriptive studies; such as comparative studies, correlation 
studies and case control studies
IV Evidence obtained from expert committee reports or opinions 
and/or clinical experience of respected authorities
Table 2. Grading recommendations11.
Recommendation Description Methodological quality of supporting evidence Implications
Grade 1A Strong recommendation, 
high-quality evidence
RCTs without important limitations or 
overwhelming evidence from observational studies
Strong recommendation, can 
apply to most patients in most 
circumstances without reservation
Grade 1B Strong recommendation, 
moderate-quality 
evidence
RCTs with important limitations (inconsistent 
results, methodological flaws, indirect or 
imprecise) or exceptionally strong evidence from 
observational studies
Strong recommendation, can 
apply to most patients in most 
circumstances without reservation
Grade 1C Strong recommendation, 
low-quality or very low-
quality evidence
Observational studies or case series Strong recommendation, but 
may change when higher quality 
evidence becomes available
Grade 2A Weak recommendation, 
high-quality evidence
RCTs without important limitations or 
overwhelming evidence from observational studies
Weak recommendation, best 
action may differ depending on 
circumstances or patients or 
societal values
Grade 2B Weak recommendation, 
moderate-quality 
evidence
RCTs with important limitations (inconsistent 
results, methodological flaws, indirect or 
imprecise) or exceptionally strong evidence from 
observational studies
Weak recommendation, best 
action may differ depending on 
circumstances or patients or 
societal values
Grade 2C Weak recommendation, 
low-quality or very low-
quality evidence
Observational studies or case series Weak recommendation, other 
alternatives may be equally 
reasonable
RCT: Randomized controlled trial.
Table 3. Summary of treatments and recommendation levels used for neuromyelitis optica.
Treatment Dose/Regimen Recommendation Evidence level
Acute attacks
Corticosteroid pulse (HIMP) Methylprednisolone 1g/day for 3 to 5 days Grade 1C III
Plasmapheresis (PE) 2 ~ 4 liters per session, 2 to 3 sessions per week, up to 7 sessions Grade 1C IIb
Relapse prevention
Oral prednisone 5 ~ 20 mg/day Grade 1C III
Azathioprine 2 mg/kg/day Grade 1C III
Mycophenolate mofetil 2 g/day Grade 1C III
Rituximab 375 mg/m2/week for 4 weeks or 1g repeated in 2 weeks; 
monitoring of CD19+ or CD27+ B cells to indicate retreatment
Grade 1C III
Immunoglobulin (IVIG) 400 mg/kg for 5 days monthly Grade 2C IV
Mitoxantrone 12 mg/m2/month, maximum cumulative dose 140 mg/m2 Grade 2C III
Cyclophosphamide 1 g/day monthly or immunoablation with 2 g/day for 4 days Grade 2C IV
HIMP: High-dose intravenous methylprednisolone; PE: plasmapheresis; IVIG: intravenous immunoglobulin.
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is an extracorporeal blood purification technique designed 
to remove antibodies, complement, cytokines and chemok-
ines from the plasma. The quick removal of these substances 
may reduce further damage and interrupt the advancement 
of lesions faster than immunosuppressive agents, as autoan-
tibodies can persist for several weeks in the circulation. It has 
been largely used for the treatment of thrombotic thrombo-
cytopenic purpura, myasthenia gravis, chronic inflammatory 
demyelinating polyneuropathy, Waldenstrom macroglobu-
linemia and Guillain-Barré syndrome15. MS, NMO, acute dis-
seminated encephalomyelitis, Lambert-Eaton myasthenic 
syndrome, paraproteinemic polyneuropathy and cryoglobu-
linemic polyneuropathy are some other neurological condi-
tions sometimes treated with apheresis16. Due to the success 
in other immune mediate diseases, PE is used in NMO tak-
ing into consideration that there is evidence that NMO is an 
autoantibody-mediated disease with complement activation 
and PE has the potential to remove humoral immune prod-
ucts from systemic circulation17.
PE is often prescribed using at least five plasma exchange 
sessions to achieve a sufficient antibody removal. The rate of 
extravascular to intravascular equilibration is approximately 
one to two percent per hour, then five separate exchanges 
over seven to ten days are required to remove 90% of the to-
tal initial body immunoglobulin levels18. In order to be most 
effective, PE has to be associated with appropriate immuno-
suppressant therapy, avoiding new immunoglobulin produc-
tion. If antibody production is not properly blocked, addi-
tional PE sessions may be required.
PE is an invasive therapeutic procedure and carries some 
complications. In NMO, it is usually performed using 5% al-
bumin replacement, so complications from fresh frozen plas-
ma infusion are avoided. Reported adverse effects have been 
hypotension, dyspnea/pulmonary edema due to fluid over-
load, citrate induced hypocalcaemia, coagulation abnormali-
ties, infection and catheter related issues. As PE can also pro-
mote removal from serum of drugs such as azathioprine and 
cyclophosphamide; it is advisable that these drugs are ad-
ministered following apheresis sessions19.
There is some evidence from some case series that PE is 
effective for acute relapse treatment in NMO patients who 
did not respond satisfactorily to HIMP5,17,20,21. Moreover, clini-
cal response seems to be related to the early initiation of treat-
ment20 and it may be observed quickly once PE sessions are 
started5. A review from the American Academy of Neurology 
about PE in neurological diseases indicates that there is Class 
II evidence that PE is probably effective to treat fulminant 
CNS diseases, including NMO22. However, the randomized 
study which provided such evidence included 22 patients 
with various CNS demyelinating diseases, like MS, ADEM, 
Marburg’s disease, but only four patients with acute myelitis 
and two patients with NMO23. Other small case series have 
reported positive results with double membrane filtration 
plasmapheresis (instead of centrifugation technique)24 and 
PE used as rescue therapy 25.
The Guidelines on the use of therapeutic apheresis in 
clinical practice from the American Society for Apheresis 
published in 201026 considered that PE for NMO is accepted 
as second line therapy, as it may be helpful in recovery from 
acute attacks, although it does not prevent further relapses. 
For long-term treatment, there is only a small case-series 
study (n=4) indicating that PE is effective not only for acute 
management, but also intermittent PE may be worthwhile 
for selected cases where long-term immunosuppressant 
treatment have failed21.
AzAThIOPRINE
Azathioprine is a DNA synthesis inhibitor, as it is converted 
to a purine analogue, with interference in the purines synthe-
sis (adenine and guanine). It inhibits the proliferation of cells, 
especially lymphocytes. The clinical effects are usually not seen 
before three to six months after initiation of therapy. It is a rea-
sonably well-tolerated drug used for autoimmune diseases 
and organ transplantation either alone or in combination. It 
has been approved as adjunctive therapy in prevention of re-
jection of kidney transplants and for the management of active 
rheumatoid arthritis27. Additionally, many off-label uses have 
been reported, such as adjunct in prevention of solid organ 
transplants rejection, steroid-sparing agent for corticosteroid-
dependent Crohn’s disease and ulcerative colitis, dermatomy-
ositis/polymyositis, MS and other autoimmune diseases. 
Common adverse events reported with azathioprine in-
clude: fever, malaise, nausea, vomiting, leukopenia, thrombo-
cytopenia, hepatoxicity, myalgia, and infections. It is reported 
a slight higher risk of developing cancer27. Therefore, periodic 
monitoring of patients with hematological (complete blood 
count with differential and platelets), liver function tests, bili-
rubin and continuous surveillance for clinical signs of cancer 
are required.
More recently, there is increasing evidence to evaluate 
thiopurine methyltransferase enzyme activity before initiat-
ing azathioprine therapy28. Thiopurine methyltransferase en-
zyme is involved in the metabolism of azathioprine and may 
determine the clinical response to thiopurines. Patients with 
intermediate or low thiopurine methyltransferase activity 
may be at risk for increased myelosuppression, sometimes 
life-threatening. Therefore, careful monitoring and dose ad-
justments may be required for these patients.
As previously described, the first study included seven 
newly diagnosed NMO patients with long-term combination 
of corticosteroids and azathioprine with positive results6. 
HIMP was given first for five days, followed by oral predni-
sone (1 mg/kg/day) for two months daily. At week three, pa-
tients started azathioprine (2 mg/kg/day). Two months later, 
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patients began prednisone tapering very slowly until they 
have achieved a dose of 10 mg/day and azathioprine doses 
of 75 to 100 mg/day. Another study observed that suspension 
of azathioprine was followed by increase in AQP-4 antibody 
levels and clinical attacks in some patients, together with the 
interruption of corticosteroid in two patients or the main-
tenance of low-dose corticosteroid treatment (5 mg/day)9. A 
retrospective study with 36 Brazilian NMO patients analyzed 
those who used azathioprine alone or in combination with 
corticosteroids and provided similar findings of reduction 
in disability and relapse rates29. These results may indicate 
that combination therapy may be required in some patients. 
However, there are no multicenter controlled studies to pro-
vide class I efficacy evidence of this therapeutic regimen, and 
side effects may limit the use in some patients.
RITUxIMAB
Rituximab is a chimeric monoclonal antibody against the 
protein CD20, which is primarily found on the surface of B 
cells and it has the property to eliminate B cells selectively. 
Rituximab binds to the antigen on the cell surface, activat-
ing complement-dependent B cell cytotoxicity. It also binds 
to human Fc receptors, mediating cell killing through an an-
tibody-dependent cellular toxicity. Rituximab is used in the 
treatment of many lymphomas, leukemias, transplant re-
jection and some autoimmune disorders. Besides the clini-
cal studies with rituximab, another evidence that B cells and 
AQP-4 antibody are closely related to NMO pathogenesis is a 
case report of a Japanese NMO patient with hypogammaglob-
ulinemia secondary to carbamazepine who reported no re-
lapses during the lowered IgG levels, but who had no attacks 
relapsed later when the hypogammaglobulinemia resolved in 
association with the normalization of CD19+ cells30. 
The first published open label study included eight patients 
in the USA, where rituximab was well tolerated, and positive 
response was observed in all patients with significant relapse 
reduction (2.6 relapse/patient/year to 0) and recovery of neu-
rologic function measured by EDSS from 7.5 to 5.531. Rituximab 
was administered in four infusions of 375 mg/m2, administered 
once per week, and B cells were monitored with CD19 marker 
by flow cytometry. In the retreatment, the regimen used was 
1,000 mg administered two weeks apart. However, one patient 
who did not receive the repeated course of rituximab when 
planned had an attack, indicating that treatment requires re-
peated infusions in order to CD19+ cells remain undetectable. 
A report of three Japanese NMO cases who received rituximab 
also observed positive results, with a remarkable reduction in 
the annualized relapse rate ( from 5.0 in the pre-treatment to 
0.6 in the post-treatment), but the decrease in EDSS was not 
so significant ( from 8.7 in the pre-treatment to 8.0 post-treat-
ment), maybe indicating that, although the drug was effective 
to control the inflammatory response, the irreversible dam-
age had already been established32. Another study described 
two NMO cases treated with rituximab33. It was observed a 
good clinical response in one patient, but the other one have 
experienced relapses after the treatment, indicating that not 
all patients respond so well. A possible explanation for the oc-
currence of relapses following initiation of rituximab in some 
NMO patients is the transient increase in AQP-4 antibody ti-
ters and of B cell activating factor levels, which is observed for 
two weeks following the initial infusion34. Posterior reversible 
encephalopathy syndrome after rituximab infusion in NMO 
have been reported35, but this syndrome has been reported 
in NMO patients independent of rituximab36, so this may be a 
relapse related to rituximab initiation rather than a new treat-
ment complication.
Another study retrospectively analyzed 25 NMO patients 
identified in seven centers from USA and Europe35. It was ob-
served a marked reduction in the attacks and improvement in 
disability. The study had the two regimen of rituximab used in pre-
vious studies analyzed together ( four infusions of 375 mg/m2, ad-
ministered once per week, and 1,000 mg administered two weeks 
apart). The median follow-up was 19 months, and the mean 
post-treatment relapse rate dropped from 1.7 to 0. Disability 
has improved in 80% of patients, but two patients died during 
the study period, one due to a brainstem relapse and the oth-
er due to suspected septicemia. The study indicated a prom-
ising treatment option, but, like the traditional chemother-
apies, it may expose patients to severe infections. Another 
retrospective study in the USA has also revealed that ritux-
imab treatment was associated with reduction of relapses 
and stabilization or improvement of disability36.
A study with eight European patients evaluated the clini-
cal response and AQP-4 antibody titers with different treat-
ments, measured by a fluorescence immunoprecipitation as-
say using an extract from cells transfected with EGFP-tagged 
human AQP-4 M1 and M23 isoforms9. Four patients received 
rituximab and the reduction of CD19+ cells was correlated 
with a reduction of AQP-4 antibody titers and positive clini-
cal response. The study also identified that relapses were pre-
ceded or paralleled by reoccurrence of CD19+ cells and an in-
crease up to three-fold in the AQP-4 antibody. Another group 
has also confirmed clinical efficacy of rituximab in 10 NMO 
patients in Europe, but there was no correlation with AQP-4 
antibody levels37.
Recently, the results of an open-label study with Korean 
NMO patients were reported with positive results38. Induction 
therapy was basically the same of previous studies, followed 
by maintenance therapy with repeated rituximab infusions 
(375 mg/m2, once) when the frequency of CD27+ memory B 
cells was more than 0.05% in peripheral blood. Interestingly, 
this approach reduced the number of infusions in the main-
tenance therapy, with a direct impact on treatment costs. 
Twenty-eight of 30 patients (93%) showed a marked reduction 
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in the mean relapse rate from 2.4 to 0.3 while receiving ritux-
imab over 24 months. Seventy percent of patients became 
relapse-free over 24 months, and disability either improved 
or stabilized in great majority of patients. One patient con-
tinued to have relapses despite rituximab treatment and was 
switched to mitoxantrone hydrochloride, and another patient 
had three relapses during treatment, but two relapses were 
associated with delayed retreatment. AQP-4 antibody levels 
declined significantly following treatment with rituximab, 
consistent with the clinical response and the effect on memo-
ry B cells. The most common infusion-related reactions, not-
ed in 40% of patients during the first infusion, were transient 
hypotension and mild to moderate flu-like symptoms, such 
as a febrile sense, headache and skin rash. Less than half of 
patients experienced at least one infection episode during the 
study period, but there were no serious infection. There was 
no decline in serum total IgG titers, and no patient became 
seropositive for the JC virus over the 24 months.
MITOxANTRONE
Mitoxantrone hydrochloride is an anthracenedione used 
as an antineoplastic agent for prostate cancer and acute non-
lymphocytic leukemia in adults. It has been approved for MS 
treatment, including secondary progressive MS, based on the 
evidence that it has reduced progression in MS patients with 
failure in other treatment regimens. It also reduces the clini-
cal relapse rate and MRI outcomes in relapsing-remitting MS 
patients, and it is helpful on patients with clinical worsening 
conditions. However, the potential toxicity of this drug limits 
its use, and patients should be monitored periodically for car-
diac, liver and kidney function39.
Considering the successful use in MS, mitoxantrone has 
been evaluated in NMO patients, but the case series have 
been very limited. In a study, five NMO patients received 
monthly intravenous infusions of mitoxantrone hydrochlo-
ride, 12 mg/m2, for six months, followed by three additional 
treatments every three months40. During the two years peri-
od of treatment, two patients had a relapse within the initial 
five months of treatment (one severe and one moderate), and 
improvement was seen clinically and on magnetic resonance 
images in four patients. One patient had a reversible decrease 
in cardiac ejection fraction. In another study, there were three 
patients who received mitoxantrone9. Unfortunately, the re-
sponse was variable, from reduction of relapse rate in one pa-
tient to increased relapse rate in two patients. 
MyCOPhENOLATE MOfETIL
Mycophenolate mofetil has been largely used for the 
treatment of several autoimmune diseases. It has a selective 
cytostatic effect on T and B lymphocytes. It is an inhibitor 
of inosine monophosphate dehydrogenase, which inhibits de 
novo guanosine nucleotide synthesis, required for prolifera-
tion of T and B lymphocytes. It has been used for prevention 
of organ transplants rejection and autoimmune diseases, like 
myasthenia gravis and systemic lupus erythematosus. 
In 2006, a case report described a NMO patient success-
fully treated with mycophenolate mofetil 2 g/day who had no 
relapses over the following two years associated with clinical 
improvement41. Another study analyzed retrospectively 24 
patients treated with mycophenolate mofetil (median dose 
of 2 g/day) with median treatment duration of 27 months. 
Patients had reduction in relapse rates (median annualized 
rate dropped from 1.28 to 0.09) and 91% of patients had sta-
bilization or improvement of disability. In this study, six pa-
tients (25%) reported adverse events, which included head-
ache, constipation, easy bruising, anxiety, hair loss, diarrhea 
and abdominal pain, and low white blood cell counts that re-
quired discontinuation42.
CyCLOPhOSPhAMIDE
Cyclophosphamide is an alkylating agent that prevents 
cell division by cross-linking DNA strands and decreasing 
DNA synthesis. It is a cell cycle phase nonspecific agent and 
has immunosuppressant activity. Cyclophosphamide is a 
prodrug that must be metabolized to active metabolites in 
the liver. It has been used in the treatment of many neopla-
sias and some autoimmune diseases, like severe rheumatoid 
disorders, Wegener’s granulomatosis, myasthenia gravis, MS, 
systemic lupus erythematosus, autoimmune hemolytic ane-
mia and idiopathic thrombocytopenic purpura. 
However, most studies are based on open-label studies 
or case series. In MS, the largest study from the Canadian 
Co-operative Multiple Sclerosis Study Group with 168 pa-
tients failed to demonstrate clinical efficacy of cyclophosph-
amide43. Another study has indicated some beneficial effects 
of cyclophosphamide in young MS patients, excluding those 
with primary progressive MS. In this study, the responsive pa-
tients received repeated cyclophosphamide infusions in a bi-
monthly basis after the induction phase44. Common adverse 
events of cyclophosphamide include: alopecia, fertility issues, 
nausea and vomiting, anorexia, diarrhea, mucositis, acute 
hemorrhagic cystitis or urinary fibrosis, anemia, leukopenia 
(dose-related with recovery from seven to ten days after ces-
sation) and thrombocytopenia.
In NMO, there is scarce data, based mainly in case re-
ports. The use of cyclophosphamide has been reported as ef-
fective in immunoablative doses (2,000 mg/day for 4 days) 
in a patient with NMO associated with refractory systemic 
lupus erythematosus after response failure with other treat-
ments, like HIMP, intravenous immunoglobulin (IVIG) and 
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rituximab45. However, another case report indicated a fail-
ure of monthly cyclophosphamide pulse (1,000 mg/m2) for 
six months, although NMO relapses were controlled with 
rituximab46.
INTERfERON BETA
The therapy using interferon beta has been used in MS 
treatment in routine practice for over 15 years. However, in-
terferon beta is not currently recommended for NMO pa-
tients and there are some evidences that it also may be even 
harmful, increasing the relapse rates47. Other Japanese stud-
ies reported MS patients with good response to interferon 
beta therapy, compared with NMO patients who experienced 
increased relapse rate after interferon beta treatment48,49. 
Similarly, a series of 25 NMO patients from France were re-
ported to experience relapses following treatment with inter-
feron beta50. Additionally, there is a case report of a Caucasian 
NMO patient from United Kingdom51, suggesting that this 
deleterious response to interferon beta is probably not influ-
enced by racial differences.
OThER ThERAPIES AND fUTURE PERSPECTIVES
Eculizumab is a humanized monoclonal IgG antibody 
that binds to complement protein C5, preventing cleavage 
into C5a and C5b. Eculizumab inhibits the subsequent for-
mation of terminal complex C5b-9 or membrane attack com-
plex. It is currently under investigation for NMO in an open-
label phase I clinical trial at a single center with 14 patients52. 
Eculizumab has already been shown to be effective in parox-
ysmal nocturnal hemoglobinuria53. Each patient will receive 
eculizumab at a dose of 600 mg each week for four weeks, 
then 900 mg at the fifth week, and 900 mg every two weeks 
for 48 weeks.
Anecdotal reports have been published using intrave-
nous immunoglobulin54, glatiramer acetate55, but replication 
of these findings needs to be validated by other studies in a 
larger number of patients. 
Other monoclonal antibodies used in MS treatment have 
been tried in NMO patients refractory to established treat-
ments, like natalizumab, but NMO patients seem to not re-
spond to these therapies (personal communication with Dr 
Anu Jacob, The Walton Centre, Liverpool UK, unpublished).  
fINAL REMARkS
The use of corticosteroids and other immunosuppres-
sant drugs for NMO treatment has been based on case re-
ports or small series of cases rather than in double-blinded 
randomized studies. This does not mean that these drugs are 
not effective, but that higher levels of evidence of their effec-
tiveness are still lacking. As NMO is a very severe and inca-
pacitating CNS disorder, its treatment has to be decided on 
the basis of clinical judgment, physicians’ experience, case 
series and extrapolation from management of other autoim-
mune conditions while clinical trials are not yet available to 
provide physicians with options grounded on stronger scien-
tific support.
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